Malgorzata Kasztan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Malgorzata Kasztan has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- David M. Pollock
University of Alabama at Birmingham
4 shared publications - Kelly Anne Hyndman
University of Alabama at Birmingham
3 shared publications - Nigel S. Key
Department of Medicine Division of Hematology and Blood Research Center University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
3 shared publications - Rafal Pawlinski
Division of Hematology, Department of Medicine, Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC
3 shared publications Bryant J. Kane
University of North Carolina at Chapel Hill
2 shared publications- Erica Marie Sparkenbaugh
University of North Carolina at Chapel Hill
2 shared publications
Latest Publications
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F633-F647
A model of recurrent heat stress that causes kidney injury in mice
Here we present a recurrent heat stress model that produces consistent increases in core temperature and dehydration with each event, leading to kidney injury in male and female mice. This robust and reproducible model demonstrates that repeated heat exposure drives sustained kidney injury, inflammation, and functional decline. It offers a valuable platform for mechanistic investigation and therapeutic development relevant to CKD of nontraditional origin.
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F633-F647
A model of recurrent heat stress that causes kidney injury in mice
Here we present a recurrent heat stress model that produces consistent increases in core temperature and dehydration with each event, leading to kidney injury in male and female mice. This robust and reproducible model demonstrates that repeated heat exposure drives sustained kidney injury, inflammation, and functional decline. It offers a valuable platform for mechanistic investigation and therapeutic development relevant to CKD of nontraditional origin.
- Open Access
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F655-F672
Impact of renal iron overload on sickle cell nephropathy in a humanized mouse model
SCD, an inherited hemolytic anemia, is associated with increased mortality from prolonged iron overload. Current interventional strategies are limited to the chelation of transfusion-mediated iron overload only, leaving kidney-specific, hemolysis-driven iron burden unaddressed. This study provided preclinical evidence that iron chelation prevents kidney-specific iron overload and subsequent kidney injury in a murine model of SCD. Thus, iron chelation of systemic- and transfusion-independent renal iron accumulation may slow the progression of SCD nephropathy.
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F655-F672
Open AccessImpact of renal iron overload on sickle cell nephropathy in a humanized mouse model
SCD, an inherited hemolytic anemia, is associated with increased mortality from prolonged iron overload. Current interventional strategies are limited to the chelation of transfusion-mediated iron overload only, leaving kidney-specific, hemolysis-driven iron burden unaddressed. This study provided preclinical evidence that iron chelation prevents kidney-specific iron overload and subsequent kidney injury in a murine model of SCD. Thus, iron chelation of systemic- and transfusion-independent renal iron accumulation may slow the progression of SCD nephropathy.
- Open Access
- 1 January 2026
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 104, 1-11
Endothelin receptor antagonism in sickle cell disease: Is the time now?
Sickle cell disease (SCD) is a severe heritable hemoglobinopathy characterized by chronic hemolysis, episodic vaso-occlusion, and progressive multi-organ damage. Although hydroxyurea remains the most established disease-modifying therapy and that newer approaches such as L-glutamine, voxelotor, crizanlizumab, and gene therapy have expanded the therapeutic landscape, important limitations remain. These include incomplete efficacy, recent clinical or regulatory setbacks, as well as high cost and access barriers. Thus, safe, accessible, and mechanistically targeted treatments remain urgently needed, particularly for patients with progressive end-organ injury. Mounting evidence implicates the peptide endothelin-1 (ET-1) as a mediator of SCD pathology, and blockade of one of its primary receptors, endothelin receptor A (ET A ), may ameliorate several adverse effects. In humanized SCD mice, selective ET A antagonism provides robust nephroprotection, while Phase I clinical data suggest a favorable safety profile in addition to signals of improved albuminuria and vascular function. In parallel, selective ET A antagonists have rapidly advanced owing to multiple FDA approvals for proteinuric kidney diseases outside the context of SCD, in addition to approvals as antihypertensives. Here, we highlight emerging evidence supporting endothelin pathway blockade as a potential targeted therapy for complications such as sickle cell nephropathy, vasculopathy, and pain, while discussing key considerations for future trials.
- 1 January 2026
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 104, 1-11
Open AccessEndothelin receptor antagonism in sickle cell disease: Is the time now?
Sickle cell disease (SCD) is a severe heritable hemoglobinopathy characterized by chronic hemolysis, episodic vaso-occlusion, and progressive multi-organ damage. Although hydroxyurea remains the most established disease-modifying therapy and that newer approaches such as L-glutamine, voxelotor, crizanlizumab, and gene therapy have expanded the therapeutic landscape, important limitations remain. These include incomplete efficacy, recent clinical or regulatory setbacks, as well as high cost and access barriers. Thus, safe, accessible, and mechanistically targeted treatments remain urgently needed, particularly for patients with progressive end-organ injury. Mounting evidence implicates the peptide endothelin-1 (ET-1) as a mediator of SCD pathology, and blockade of one of its primary receptors, endothelin receptor A (ET A ), may ameliorate several adverse effects. In humanized SCD mice, selective ET A antagonism provides robust nephroprotection, while Phase I clinical data suggest a favorable safety profile in addition to signals of improved albuminuria and vascular function. In parallel, selective ET A antagonists have rapidly advanced owing to multiple FDA approvals for proteinuric kidney diseases outside the context of SCD, in addition to approvals as antihypertensives. Here, we highlight emerging evidence supporting endothelin pathway blockade as a potential targeted therapy for complications such as sickle cell nephropathy, vasculopathy, and pain, while discussing key considerations for future trials.
- Open Access
- 29 May 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (11) , 2709-2721
Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model
Sickle cell trait (SCT) is present in participants who possess a single copy of the βS-globin gene mutation. Although most affected individuals are asymptomatic, SCT is a well-established risk factor for venous thrombosis and renal complications, including chronic and end-stage kidney disease. After prolonged hypoxia, SCT red blood cells (RBCs) can undergo sickling, and hypoxia-mediated RBC sickling can be enhanced by cellular dehydration, hyperosmolarity, and/or acidosis. Some or all of these conditions may be encountered in the nidus of venous thrombi and in the medulla of the kidney. We sought to determine whether Townes sickle trait (AS) mice develop kidney dysfunction and manifest enhanced venous thrombosis. We demonstrated that the harsh environment within the inner medulla induces RBC sickling in vitro and in vivo and is associated with kidney-related pathologies, including impaired urinary concentration, albuminuria, and declining renal function, closely mimicking those seen in human SCT. In the inferior vena cava model of venous thrombosis, extreme and prolonged hypoxia in the core of RBC-rich venous thrombi resulted in irreversible RBC sickling and larger clots in Townes AS mice than AA controls (littermates expressing hemoglobin A only). Our results support the use of Townes AS mice in future studies investigating mechanisms of venous thrombosis and chronic kidney disease in SCT.
- 29 May 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (11) , 2709-2721
Open AccessAddressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model
Sickle cell trait (SCT) is present in participants who possess a single copy of the βS-globin gene mutation. Although most affected individuals are asymptomatic, SCT is a well-established risk factor for venous thrombosis and renal complications, including chronic and end-stage kidney disease. After prolonged hypoxia, SCT red blood cells (RBCs) can undergo sickling, and hypoxia-mediated RBC sickling can be enhanced by cellular dehydration, hyperosmolarity, and/or acidosis. Some or all of these conditions may be encountered in the nidus of venous thrombi and in the medulla of the kidney. We sought to determine whether Townes sickle trait (AS) mice develop kidney dysfunction and manifest enhanced venous thrombosis. We demonstrated that the harsh environment within the inner medulla induces RBC sickling in vitro and in vivo and is associated with kidney-related pathologies, including impaired urinary concentration, albuminuria, and declining renal function, closely mimicking those seen in human SCT. In the inferior vena cava model of venous thrombosis, extreme and prolonged hypoxia in the core of RBC-rich venous thrombi resulted in irreversible RBC sickling and larger clots in Townes AS mice than AA controls (littermates expressing hemoglobin A only). Our results support the use of Townes AS mice in future studies investigating mechanisms of venous thrombosis and chronic kidney disease in SCT.
- Open Access
- 16 November 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (22) , 6850-6858
Natural history and variability in albuminuria in pediatric and murine sickle cell anemia
It is critical to characterize the natural history of albuminuria in patients with sickle cell anemia (SCA); however, these data are currently lacking and affecting evidence-based guidelines. We performed a natural history study of the development of pediatric albuminuria. We identified participants with hemoglobin SS/SB0 thalassemia ≥5 years with albumin to creatinine ratio (ACR) measurements performed at a steady-state clinic visit. Participants were characterized as either persistent, intermittent, or never albuminuria. We determined the prevalence of persistent albuminuria, use of ACR ≥100 mg/g as a predictor, and variation in ACR measurements. We mirrored this study to determine the variation in albuminuria measurements in the SCA murine model. Among 355 participants with HbSS/SB0 thalassemia with 1728 ACR measurements, we identified 17% with persistent and 13% with intermittent albuminuria. Thirteen percent of participants with persistent albuminuria developed an abnormal ACR before 10 years of age. A single ACR measurement ≥100 mg/g was associated with 55.5 times (95% confidence interval, 12.3-527) higher odds of having persistent albuminuria. Among participants with ACR ≥100 mg/g, we identified significant variability in the results of repeated measurements. The median ACR at the initial and next measurements were 175.8 mg/g (interquartile range [IQR], 135-242) and 117.3 mg/g (IQR, 64-292). The human variability in ACR was mirrored by ∼20% variability in albuminuria in murine model. This evidence suggests adopting standards for repeating ACR measurements, consider screening for ACR before 10 years of age, and using an ACR >100 mg/g as a risk factor for progression. Pediatric and murine renoprotective clinical trials need to consider the high variability in repeated ACR measurements.
- 16 November 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (22) , 6850-6858
Open AccessNatural history and variability in albuminuria in pediatric and murine sickle cell anemia
It is critical to characterize the natural history of albuminuria in patients with sickle cell anemia (SCA); however, these data are currently lacking and affecting evidence-based guidelines. We performed a natural history study of the development of pediatric albuminuria. We identified participants with hemoglobin SS/SB0 thalassemia ≥5 years with albumin to creatinine ratio (ACR) measurements performed at a steady-state clinic visit. Participants were characterized as either persistent, intermittent, or never albuminuria. We determined the prevalence of persistent albuminuria, use of ACR ≥100 mg/g as a predictor, and variation in ACR measurements. We mirrored this study to determine the variation in albuminuria measurements in the SCA murine model. Among 355 participants with HbSS/SB0 thalassemia with 1728 ACR measurements, we identified 17% with persistent and 13% with intermittent albuminuria. Thirteen percent of participants with persistent albuminuria developed an abnormal ACR before 10 years of age. A single ACR measurement ≥100 mg/g was associated with 55.5 times (95% confidence interval, 12.3-527) higher odds of having persistent albuminuria. Among participants with ACR ≥100 mg/g, we identified significant variability in the results of repeated measurements. The median ACR at the initial and next measurements were 175.8 mg/g (interquartile range [IQR], 135-242) and 117.3 mg/g (IQR, 64-292). The human variability in ACR was mirrored by ∼20% variability in albuminuria in murine model. This evidence suggests adopting standards for repeating ACR measurements, consider screening for ACR before 10 years of age, and using an ACR >100 mg/g as a risk factor for progression. Pediatric and murine renoprotective clinical trials need to consider the high variability in repeated ACR measurements.
- Open Access
- 13 April 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (15) , 1871-1883
Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease
A hypercoagulable state, chronic inflammation, and increased risk of venous thrombosis and stroke are prominent features in patients with sickle cell disease (SCD). Coagulation factor XII (FXII) triggers activation of the contact system that is known to be involved in both thrombosis and inflammation, but not in physiological hemostasis. Therefore, we investigated whether FXII contributes to the prothrombotic and inflammatory complications associated with SCD. We found that when compared with healthy controls, patients with SCD exhibit increased circulating biomarkers of FXII activation that are associated with increased activation of the contact pathway. We also found that FXII, but not tissue factor, contributes to enhanced thrombin generation and systemic inflammation observed in sickle cell mice challenged with tumor necrosis factor α. In addition, FXII inhibition significantly reduced experimental venous thrombosis, congestion, and microvascular stasis in a mouse model of SCD. Moreover, inhibition of FXII attenuated brain damage and reduced neutrophil adhesion to the brain vasculature of sickle cell mice after ischemia/reperfusion induced by transient middle cerebral artery occlusion. Finally, we found higher FXII, urokinase plasminogen activator receptor, and αMβ2 integrin expression in neutrophils of patients with SCD compared with healthy controls. Our data indicate that targeting FXII effectively reduces experimental thromboinflammation and vascular complications in a mouse model of SCD, suggesting that FXII inhibition may provide a safe approach for interference with inflammation, thrombotic complications, and vaso-occlusion in patients with SCD.
- 13 April 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (15) , 1871-1883
Open AccessFactor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease
A hypercoagulable state, chronic inflammation, and increased risk of venous thrombosis and stroke are prominent features in patients with sickle cell disease (SCD). Coagulation factor XII (FXII) triggers activation of the contact system that is known to be involved in both thrombosis and inflammation, but not in physiological hemostasis. Therefore, we investigated whether FXII contributes to the prothrombotic and inflammatory complications associated with SCD. We found that when compared with healthy controls, patients with SCD exhibit increased circulating biomarkers of FXII activation that are associated with increased activation of the contact pathway. We also found that FXII, but not tissue factor, contributes to enhanced thrombin generation and systemic inflammation observed in sickle cell mice challenged with tumor necrosis factor α. In addition, FXII inhibition significantly reduced experimental venous thrombosis, congestion, and microvascular stasis in a mouse model of SCD. Moreover, inhibition of FXII attenuated brain damage and reduced neutrophil adhesion to the brain vasculature of sickle cell mice after ischemia/reperfusion induced by transient middle cerebral artery occlusion. Finally, we found higher FXII, urokinase plasminogen activator receptor, and αMβ2 integrin expression in neutrophils of patients with SCD compared with healthy controls. Our data indicate that targeting FXII effectively reduces experimental thromboinflammation and vascular complications in a mouse model of SCD, suggesting that FXII inhibition may provide a safe approach for interference with inflammation, thrombotic complications, and vaso-occlusion in patients with SCD.
- 1 July 2022
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 100 (7) , 637-650
Endothelin A receptor antagonist attenuated renal iron accumulation in iron overload heme oxygenase-1 knockout mice
Progressive iron accumulation and renal impairment are prominent in both patients and mouse models of sickle cell disease (SCD). Endothelin A receptor (ETA) antagonism prevents this iron accumulation phenotype and reduces renal iron deposition in the proximal tubules of SCD mice. To better understand the mechanisms of iron metabolism in the kidney and the role of the ETA receptor in iron chelation and transport, we studied renal iron handling in a nonsickle cell iron overload model, heme oxygenase-1 ( Hmox-1−/−) knockout mice. We found that Hmox-1−/− mice had elevated plasma endothelin-1 (ET-1), cortical ET-1 mRNA expression, and renal iron content compared with Hmox-1+/+ controls. The ETA receptor antagonist, ambrisentan, attenuated renal iron deposition, without any changes to anemia status in Hmox-1−/− mice. This was accompanied by reduced urinary iron excretion. Finally, ambrisentan had an important iron recycling effect by increasing the expression of the cellular iron exporter, ferroportin-1 (FPN-1), and circulating total iron levels in Hmox-1−/− mice. These findings suggest that the ET-1/ETA signaling pathway contributes to renal iron trafficking in a murine model of iron overload.
- 1 July 2022
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 100 (7) , 637-650
Endothelin A receptor antagonist attenuated renal iron accumulation in iron overload heme oxygenase-1 knockout mice
Progressive iron accumulation and renal impairment are prominent in both patients and mouse models of sickle cell disease (SCD). Endothelin A receptor (ETA) antagonism prevents this iron accumulation phenotype and reduces renal iron deposition in the proximal tubules of SCD mice. To better understand the mechanisms of iron metabolism in the kidney and the role of the ETA receptor in iron chelation and transport, we studied renal iron handling in a nonsickle cell iron overload model, heme oxygenase-1 ( Hmox-1−/−) knockout mice. We found that Hmox-1−/− mice had elevated plasma endothelin-1 (ET-1), cortical ET-1 mRNA expression, and renal iron content compared with Hmox-1+/+ controls. The ETA receptor antagonist, ambrisentan, attenuated renal iron deposition, without any changes to anemia status in Hmox-1−/− mice. This was accompanied by reduced urinary iron excretion. Finally, ambrisentan had an important iron recycling effect by increasing the expression of the cellular iron exporter, ferroportin-1 (FPN-1), and circulating total iron levels in Hmox-1−/− mice. These findings suggest that the ET-1/ETA signaling pathway contributes to renal iron trafficking in a murine model of iron overload.
- 23 June 2020
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (9) , 2329-2340
High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease
- 23 June 2020
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (9) , 2329-2340
High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease
- Open Access
- 17 January 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (2) , 263-265
Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia
- 17 January 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (2) , 263-265
Open AccessSex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia
- 15 July 2019
- Published by Portland Press Ltd. in Clinical Science
- Vol. 133 (13) , 1475-1486
Impact of ET-1 and sex in glomerular hyperfiltration in humanized sickle cell mice
Hyperfiltration, highly prevalent early in sickle cell disease (SCD), is in part driven by an increase in ultrafiltration coefficient (Kf). The increases in Kf may be due to enlarged filtration surface area and/or increased glomerular permeability (Palb). Previous studies have demonstrated that endothelin-1 (ET-1) contributes to Palb changes in models of diabetes and SCD. Thus, we performed longitudinal studies of renal function to determine the relationship between ET-1 and glomerular size and Palb that may contribute to hyperfiltration in humanized sickle cell (HbSS) and control (HbAA) mice 8 to 32 weeks of age. HbSS mice were characterized by significant increases in plasma and glomerular ET-1 expression in both sexes although this increase was significantly greater in males. HbSS glomeruli of both males and females presented with a progressive and significant increase in glomerular size, volume, and Kf. During the onset of hyperfiltration, plasma and glomerular ET-1 expression were associated with a greater increase in glomerular size and Kf in HbSS mice, regardless of sex. The pattern of Palb augmentation during the hyperfiltration was also associated with an increase in glomerular ET-1 expression, in both male and female HbSS mice. However, the increase in Palb was significantly greater in males and delayed in time in females. Additionally, selective endothelin A (ETA) receptor antagonist prevented hyperfiltration in HbSS, regardless of sex. These results suggest that marked sex disparity in glomerular hyperfiltration may be driven, in part, by ET-1-dependent ultra-structural changes in filtration barrier components contributing to glomerular hyperfiltration in HbSS mice.
- 15 July 2019
- Published by Portland Press Ltd. in Clinical Science
- Vol. 133 (13) , 1475-1486
Impact of ET-1 and sex in glomerular hyperfiltration in humanized sickle cell mice
Hyperfiltration, highly prevalent early in sickle cell disease (SCD), is in part driven by an increase in ultrafiltration coefficient (Kf). The increases in Kf may be due to enlarged filtration surface area and/or increased glomerular permeability (Palb). Previous studies have demonstrated that endothelin-1 (ET-1) contributes to Palb changes in models of diabetes and SCD. Thus, we performed longitudinal studies of renal function to determine the relationship between ET-1 and glomerular size and Palb that may contribute to hyperfiltration in humanized sickle cell (HbSS) and control (HbAA) mice 8 to 32 weeks of age. HbSS mice were characterized by significant increases in plasma and glomerular ET-1 expression in both sexes although this increase was significantly greater in males. HbSS glomeruli of both males and females presented with a progressive and significant increase in glomerular size, volume, and Kf. During the onset of hyperfiltration, plasma and glomerular ET-1 expression were associated with a greater increase in glomerular size and Kf in HbSS mice, regardless of sex. The pattern of Palb augmentation during the hyperfiltration was also associated with an increase in glomerular ET-1 expression, in both male and female HbSS mice. However, the increase in Palb was significantly greater in males and delayed in time in females. Additionally, selective endothelin A (ETA) receptor antagonist prevented hyperfiltration in HbSS, regardless of sex. These results suggest that marked sex disparity in glomerular hyperfiltration may be driven, in part, by ET-1-dependent ultra-structural changes in filtration barrier components contributing to glomerular hyperfiltration in HbSS mice.